Mankind Pharma

Mankind Pharma Debt

The Debt of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 85.11 B INR. In the previous year, Debt was 2.07 B INR — a change of 4,008.39% (higher).

Debt

85.11 BINR

YoY

4,008.39%

Last updated:

In 2025, Mankind Pharma's total debt was 85.11 B INR, a 4,008.39% change from the 2.07 B INR total debt recorded in the previous year.

The Mankind Pharma Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2020
1.34 B INR
Jan 1, 2021
2.80 B INR
Jan 1, 2022
8.84 B INR
Jan 1, 2023
1.70 B INR
Jan 1, 2024
2.07 B INR
Jan 1, 2025
85.11 B INR
The Mankind Pharma Debt history
YEARDebtYoY
85.11 BINR+4,008.39%
2.07 BINR+21.58%
1.70 BINR-80.72%
8.84 BINR+216.02%
2.80 BINR+109.44%
1.34 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Debt Details

Understanding Mankind Pharma's Debt Structure

Mankind Pharma's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Mankind Pharma's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Mankind Pharma’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Mankind Pharma’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Mankind Pharma stock

Debt of Mankind Pharma is 85.11 B INR in 2025.

Debt of Mankind Pharma changed from 2.07 B INR to 85.11 B INR, representing a 4,008.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Mankind Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mankind Pharma

All Key Metrics — Mankind Pharma